• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: FIDIA FARMACEUTICI S.P.A. HYALGAN; SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

FIDIA FARMACEUTICI S.P.A. HYALGAN; SODIUM HYALURONATE Back to Search Results
Device Problem Patient-Device Incompatibility (2682)
Patient Problems Anaphylactic Shock (1703); Presyncope (4410)
Event Date 04/24/2023
Event Type  Injury  
Event Description
This is a serious case downloaded from eudravigilance on 08-may-2023 (authority number (b)(4)); reported by consumer.On 24-apr-2023 a 46 year-old female patient started hyalgan (sodium hyaluronate).Relevant medical history included multiple allergies (ongoing) to nickel, cobalt, palladium, thiomersal, bee venom.Reactions: on (b)(6) 2023 the patient developed exanthema generalised.The outcome of the event was reported to be recovered/resolved.No actions were taken regarding the event.According to the reporter the event was life-threatening.On (b)(6) 2023 the patient developed oedema larynx.The outcome of the event was reported to be recovered/resolved.No actions were taken regarding the event.According to the reporter the event was life-threatening.On (b)(6) 2023 the patient developed pre-syncope.The outcome of the event was reported to be recovered/resolved.No actions were taken regarding the event.According to the reporter the event was life-threatening.On (b)(6) 2023 the patient developed anaphylactic reaction.The outcome of the event was reported to be recovered/resolved.No actions were taken regarding the event.According to the reporter the event was life-threatening.Reactions as reported by primary source: exanthema generalised, oedema larynx, pre-syncope, anaphylactic reaction.No further information is available.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
HYALGAN
Type of Device
SODIUM HYALURONATE
Manufacturer (Section D)
FIDIA FARMACEUTICI S.P.A.
via ponte della fabbrica 3/a
abano terme, padua 35031
IT  35031
Manufacturer (Section G)
FIDIA FARMACEUTICI S.P.A.
via ponte della fabbrica 3/a
abano terme, padua 35031
IT   35031
Manufacturer Contact
giuseppina lo castro
via ponte della fabbrica 3/a
abano terme, padua 35031
IT   35031
MDR Report Key17036892
MDR Text Key316383781
Report Number9610200-2023-00005
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeIT
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type User Facility
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 06/01/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 05/08/2023
Initial Date FDA Received06/01/2023
Was Device Evaluated by Manufacturer? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Life Threatening;
Patient Age46 YR
Patient SexFemale
-
-